List view / Grid view
7 September 2023 | By Taylor Mixides (Drug Target Review)
BlueSphere Bio's TCXpress platform revolutionises the isolation and functional characterisation of T-cell receptors (TCRs) with unparalleled speed and efficiency, enabling rapid identification of unique TCRs from thousands of individual T cells within days.
3 April 2023 | By Taylor Mixides (Drug Target Review)
A mechanism linked to a genetic mutation could help identify patients who are at higher risk of developing leukaemia.
23 November 2023 | By Drug Target Review
Discovery about the DNA of leukaemia cells suggests promising target for gene therapy in paediatric oncology.
15 January 2024 | By Drug Target Review
RBM5 removal from cells meant that HOXA9 mRNA levels were greatly reduced, which could lead to therapies targeting HOXA9-driven leukaemia.
24 April 2023 | By Izzy Wood (Drug Target Review)
US researchers find combination of chloroquine and venetoclax promotes cancer cell death in mouse models with acute myeloid leukaemia (AML).
13 April 2023 | By Taylor Mixides (Drug Target Review)
St. Jude Children's Research Hospital, US, scientists created a new combination therapy method to tackle drug resistance in a type of leukaemia with KMT2A gene rearrangement.
10 April 2024 | By Drug Target Review
The combination therapy worked faster and was lessened the number of leukaemia cells compared to asparaginase or venetoclax alone.
6 December 2023 | By Drug Target Review
Discovery about the NPM1c variant could lead to new drugs targeting the cell growth of acute myeloid leukaemia.
14 February 2024 | By Drug Target Review
Researchers have created dual-targeted CARs, which performed better than single-targeted CARs in both in vivo and in vitro experiments.
8 June 2023 | By Dr Andy Souers
Dr Andy Souers highlights the unwavering commitment to finding an enhanced therapeutic approach that eliminates the need for chemotherapy in blood cancer treatment. This transformative discovery represents a significant leap forward in the way we combat this complex disease, offering new hope to countless patients worldwide.
25 April 2023 | By Izzy Wood (Drug Target Review)
Spanish scientists have developed a new method to identify between cancerous and healthy cells for cases of acute myeloid leukaemia (AML).
6 February 2024 | By Drug Target Review
Researchers conducted a proteogenomic characterisation and found that drug exposure changes drug sensitivity.
23 July 2024 | By Drug Target Review
KDR inhibitors could be very impactful for treatment of ATLL and HAM/TSP or prevent disease by lessening the viral load of HTLV-1.
25 January 2023 | By Dr Frank Neumann (Kite Pharma)
In this Q&A, Dr Frank Neumann speaks about Kite Pharma’s work with chimeric antigen receptor (CAR) T-cell therapy and how the company is working to progress this next‑generation modality even further to help treat cancer patients.
22 December 2023 | By Drug Target Review
Using shRNA screening enabled researchers to investigate the roles of individual specific factors in maintaining the network found in AML.
